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cells and of haemopoietic stem cells in the
bone marrow indicate that Ftorafur is 2-3
times less effective than 5-FU. However, it
is about 7 times less effective in killing
rapidly proliferating haemopoietic stem cells.
This finding is hard to explain since Ftorafur
is reported to be active only through release
of 5-FU, a report which is in agreement with
our observation of ineffectiveness of Ftorafur
upon incubation in vitro in concentrations 10
times higher than effective 5-FU concentra-
tions. On the other hand, the lower toxicity
of Ftorafur for proliferating stem cells might
explain the reported better tolerance upon
prolonged administration to patients in
comparison with equally effective doses of
5-FU. A study, made to verify this, has
indicated that upon fractionated administra-
tion Ftorafur is not only much less toxic than
5-FU but also less effective in killing L 1210
cells.
If conditions in man are comparable with
those in mice, part of the good haemato-
logical tolerance to prolonged administration
of Ftorafur may be due to a decrease in the
fraction of the drug being hydrolyzed to
liberate 5-FU.
RECENT RESULTS WITH CARCINO-
GEN BINDING PROTEINS. B.
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Institute ofAnimalPhysiology. B. ABRAHAM
and J. MEUWISSEN. Katholieke Universiteit
te Leuven, Belgium.
Three azodye carcinogen binding proteins
have been purified in our laboratories with
sedimentation coefficients of 4 7, 3-5 and
1 7S. The 4 7S protein has a pl of 9 0, a low
tyrosine and a high CyS content, a complex
absorption spectrum for bound azodye and
readily dissociates into subunits.
The 3 5S protein, ligandin, is a relatively
small molecule composed of two apparently
identical subunits of MW 23,000. It never-
theless binds ligands as diverse as oestrone
sulphate, bilirubin and haematin with affinity
constants for the first binding site of 106 to
at least 108.
The abundance and wide tissue distribu-
tion ofligandin make it ofparticular interest.
An apparent connection with drug meta-
bolizing enzymes indicates that it is more
than an intracellular equivalent of serum
albumin.
LACK OF SYNERGY BETWEEN N-
METHYL-N-NITROSOUREA (MNU)
AND CYCLOPHOSPHAMIDE (CP) IN
RAT URINARY BLADDER. J. ST. J.
WAKEFIELD and R. M. HICKS. Middlesex
Hospital Medical School, London.
A single, intravesicular dose of MNU is
non-carcinogenic in the normal life span ofthe
rat. By contrast, 4 bi-weekly doses produce
bladder tumours from 15 weeks on (Hicks
and Wakefield, Chem-Biol. Interact., 1972, 5,
139). Each dose is followed by necrosis then
hyperplasia of the epithelium. Intraperi-
toneal injection of CP also causes necrosis
followed by hyperplasia of the bladder epi-
thelium, but no tumours develop after
multiple (12) doses. This suggests that pro-
longed hyperplasia per se is not carcinogenic
in the absence of some further stimulus.
Rats given either a single dose of MNU
followed by CP, or CP followed by a single
dose ofMNU, also failed to develop tumours.
These results show no co-carcinogenesis with
MNU and CP, even though the target tissue
for both compounds is the same.
SYNCARCINOGENESIS WITH N-
METHYL N-NITROSOUREA (MNU)
AND CYCLAMATE IN RAT URINARY
BLADDER. J. CHOWANIEC, J. ST. J.
WAKEFIELD and R. M. HICKS. Middlesex
Hospital Medical School, London.
Cyclamate is suspect as a bladder carci-
nogen, but reports from different experi-
mentalists are conflicting. In this laboratory,
only one animal on a cyclamate containing
diet has so far developed a bladder tumour in
the absence of any other treatment.
One intravesicular dose of MNU is not
carcinogenic but 4 doses are (Hicks and
Wakefield, Chem-Biol. Interact., 1972, 5, 139).
Animals which have received one intra-
vesicular dose of MNU are now being main-
tained on a cyclamate containing diet. Of
these, 21 animals have been killed so far and
9 had bladder tumours. These results
demonstrate syncarcinogenesis with MNU
and cyclamate in the bladder. By contrast,
co-carcinogenesis could not be demonstrated
with MNU and the cytotoxic, but not carci-
nogenic, cyclophosphamide (see previous
abstract, J. St. J. Wakefield and R. M.
Hicks). We suggest that cyclamate may be
a weak bladder carcinogen, not normally
effective in the life span of the animal.